ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients

ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients

Source: 
Fierce Pharma
snippet: 

Novartis had hoped Entresto could find itself yet another niche, this time in patients who’d had a heart attack. But in late April, a large study found the heart failure drug couldn’t quite top the widely used ACE inhibitor ramipril in those patients, at least in a statistically significant way.